Does Pharmacodynamics of Drugs Change After Presenting them as Nanoparticles Like their Pharmacokinetics?


Journal

Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531

Informations de publication

Date de publication:
2020
Historique:
received: 15 10 2019
revised: 01 12 2019
accepted: 02 12 2019
pubmed: 1 2 2020
medline: 4 6 2021
entrez: 1 2 2020
Statut: ppublish

Résumé

Nowadays, the breakthrough in different medical branches makes it feasible to designate new methods of drug delivery to achieve the most cost-effective and the least unpleasant consequenceimposing solutions to overcome a wide range of diseases. Nanoparticle (NP) drugs entered the therapeutic system, especially in cancer chemotherapy. These drugs are quite well-known for two traits of being long-acting and less toxic. For a long time, it has been investigated how NPs will change the kinetics of drugs. However, there are a few studies that inclined their attention to how NPs affect the dynamics of drugs. In this review, the latter point will mainly be discussed in an example-based manner. Besides, other particular features of NPs will be briefly noted. NPs are capable of affecting the biologic system as much as a drug. Moreover, NPs could arise a wide variety of effects by triggering their own receptors. NPs are able to change a receptor function and manipulate its downstream signaling cascade.

Identifiants

pubmed: 32003669
pii: CDT-EPUB-103971
doi: 10.2174/1389450121666200128113547
doi:

Substances chimiques

Drug Carriers 0
Receptors, Drug 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

807-818

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Razieh Mohammad Jafari (R)

Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Moein Ala (M)

Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, 13145-784, Tehran, Iran.

Navid Goodarzi (N)

Nanotechnology Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Ahmad Reza Dehpour (AR)

Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, 13145-784, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH